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Percutaneous Coronary
Intervention Outcomes With
Simple Coronary Lesions
Can That Be True?*
Stephen G. Ellis, MD
Cleveland, OhioPatients with diabetes now constitute 30% to 35% of pa-
tients undergoing revascularization in the United States (1).
Patients with diabetes have worse outcomes than those
without for both coronary intervention and bypass surgery
(2–4), and it has been strongly suggested since the publi-
cation of the results of the BARI (Bypass Angioplasty
Revascularization Investigation) study (5) that, in general,
bypass surgery is better than intervention for patients with
multivessel disease.See page 2111The biologic effects of diabetes are numerous, leading to
plaque growth, vascular instability, and risk for thrombosis
(6,7).
What is less well understood is whether the relative
beneﬁt of bypass surgery is due largely to the effect of dia-
betes per se or because patients with diabetes tend to have
much more advanced disease than those without when they
present in need of revascularization. This is of pivotal
importance, because if the main reason is that patients with
diabetes have greater lesion complexity, it might well be that
patients with diabetes presenting with “simple” anatomy
might fare just as well with percutaneous coronary inter-
vention (PCI) as bypass surgery.
Several studies bear on this issue, but none gives a
complete answer. Focusing on randomized trials in the
drug-eluting stent (DES) era, Kappetein et al. (8) reported*Editorials published in the Journal of the American College of Cardiology reﬂect the
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contents of this paper to disclose.5-year outcomes from the SYNTAX (Synergy Between
PCI With TAXUS and Cardiac Surgery) trial in patients
with diabetes with “simple lesions” (SYNTAX scores <23).
Results for composite death, myocardial infarction (MI), or
stroke were 20.1% and 19.4% (p ¼ 0.79) and for revascu-
larization were 18.5% and 38.5% (p ¼ 0.01) for coronary
artery bypass grafting (CABG) and PCI, respectively.
Outcomes for patients with diabetes with more complex
anatomy strongly favored CABG, especially when the
SYNTAX score exceeded 33. A somewhat similar pattern
was reported from the more recent FREEDOM (Future
Revascularization Evaluation in Patients With Diabetes
Mellitus: Optimal Management of Multivessel Disease)
trial, with 5-year death, MI, or stroke rates of 23% and
17% for PCI and CABG in patients with diabetes with
SYNTAX scores <23 (nominal p ¼ 0.07) and relatively
worse outcomes with PCI for patients with diabetes with
higher SYNTAX scores (9). This is admittedly a PCI-
biased view of the data, however, as both trials reported
overall better outcomes for patients with diabetes with
CABG, and analysis in this subgroup in particular must be
done with caution. Nonetheless, these are the best data we
have for patients with diabetes with relatively simple coro-
nary anatomy. The other relevant major randomized trial,
CARDIA (Coronary Artery Revascularization in Diabetes)
(all patients had diabetes), reported no difference in 5-year
mortality between PCI and CABG, but that trial has yet
to report outcomes by SYNATX score or other means of
categorizing coronary disease complexity. Also worth noting
are the results from the BARI-2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) study, wherein
patients with diabetes were randomized to revascularization
or initial conservative treatment, and in a nonrandomized
comparison, those patients chosen for CABG had fewer
major adverse outcomes than those chosen for PCI, despite
having more complex anatomy (10). Importantly, all of
these studies concerned patients with elective revasculari-
zation and not in the setting of acute coronary syndrome,
wherein PCI, even in patients with diabetes, fares well
relative to other treatment options.
To this debate is now added the report of Kedhi
et al. (11), in this issue of the Journal. They aggregated
patient-level data from 18 randomized trials of DES to
which they had access (18,441 patients) and compared
1-year adverse outcomes between those with and those
without diabetes, stratiﬁed by lesion complexity with pro-
pensity adjustment to minimize the differences between
patients with and those without diabetes. Lesion complexity
was analyzed using the modiﬁed American College of
Cardiology and American Heart Association score, which
focuses on the complexity of a single lesion, in comparison to
the SYNTAX score, which evaluates the sum of lesions’
scores. Results are summarized in Table 1.
The investigators conclude that repeat revascularization is
increased in patients with diabetes only with complex lesions
but that diabetes remains a predictor of other major adverse
Table 1
Hazard Ratio for Diabetics for Various
12-Month Endpoints
Outcome
Hazard Ratio (DM/Non-DM)
(95% Conﬁdence Interval)
Interaction p Value
(for DM vs. No DM)
Simple
Lesions
Complex
Lesions
Death, MI, TVR 1.3 (1.0–1.7) 1.6 (1.3–1.9) 0.28
Cardiac death, MI 1.7 (1.0–2.9) 1.2 (0.9–1.6) 0.28
TLR 1.0 (0.6–1.4) 1.8 (1.4–2.3) 0.01
DM ¼ diabetes mellitus; MI ¼ myocardial infarction; TLR ¼ target lesion revascularization;
TVR ¼ target vessel revascularization.
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2120cardiac events, regardless of lesion complexity. The strengths
of this analysis are the large patient number and in many
ways careful analysis. It should be recalled, however, that
most of the studies excluded patients with complex multi-
lesion anatomy, hence limiting the generalizability of the
results. In addition, it is uncertain if the results apply equally
to all DES.
How does the report of Kedhi et al. (11) advance the ﬁeld,
and how should we chose between CABG and PCI when
we are confronted with the next patient with diabetes and
coronary artery disease who requires revascularization and is
“technically suitable” for either approach? It seems that the
availability of current DES has mitigated the difference
between patients with and those without diabetes with only
a few “simple” lesions for local lesion recurrence, but not for
overall death or MI. A step forward, yes, but a small one, as
stenting does not alter the aggressive panvascular aspect of
diabetes. Can we identify patients with diabetes with simple
lesions who are at reasonably low risk for death or MI and
still need revascularization? Not surprisingly, more than
10 years of follow up in the German Diabetes Intervention
Study (12) suggests that nonsmokers with excellent control
of blood pressure, triglycerides, and blood sugar are at lowest
risk. To this, the UKPDS (United Kingdom Prospective
Diabetes Study) group adds lower low-density and higher
high-density lipoprotein levels and a nonsedentary lifestyle
as factors prognostic of better outcomes (13). Obviously,
there are other risk factors as well. Multiple studies have
shown that antiplatelet agents, statins, and angiotensin-
converting enzyme inhibitors further reduce risk (14,15).
Formal models can be used to predict diabetic risk,
although C-statistics for these models usually range from
0.60 to 0.70 (indicating only moderate predictive value)
(16).
So where do we stand? It seems in general that PCI in
patients with diabetes should still be reserved for either those
with acute coronary syndromes or elective patients with
relatively simple anatomy at the lower end of diabetic risk
spectrum for cardiovascular death or MI. Furthermore, we
need better therapies to reduce diabetic vasculopathy so thatfocal therapy of speciﬁc symptom-causing stenoses can be
associated with better long-term outcomes.
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